Left-Ventricular Function After 3 Months of Sacubitril-Valsartan in Acute Decompensated Heart Failure.

MedStar author(s):
Citation: Journal of Cardiovascular Translational Research . 14(2):290-298, 2021 04.PMID: 32557158Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Aminobutyrates/tu [Therapeutic Use] | *Angiotensin II Type 1 Receptor Blockers/tu [Therapeutic Use] | *Angiotensin-Converting Enzyme Inhibitors/tu [Therapeutic Use] | *Biphenyl Compounds/tu [Therapeutic Use] | *Heart Failure/dt [Drug Therapy] | *Protease Inhibitors/tu [Therapeutic Use] | *Valsartan/tu [Therapeutic Use] | *Ventricular Function, Left/de [Drug Effects] | Adult | Aged | Aged, 80 and over | Aminobutyrates/ae [Adverse Effects] | Angiotensin II Type 1 Receptor Blockers/ae [Adverse Effects] | Angiotensin-Converting Enzyme Inhibitors/ae [Adverse Effects] | Biphenyl Compounds/ae [Adverse Effects] | Croatia | Drug Combinations | Echocardiography | Female | Heart Failure/dg [Diagnostic Imaging] | Heart Failure/pp [Physiopathology] | Humans | Male | Middle Aged | Neprilysin/ai [Antagonists & Inhibitors] | Prospective Studies | Protease Inhibitors/ae [Adverse Effects] | Recovery of Function | Stroke Volume/de [Drug Effects] | Time Factors | Treatment Outcome | Valsartan/ae [Adverse Effects]Year: 2021ISSN:
  • 1937-5387
Name of journal: Journal of cardiovascular translational researchAbstract: There is limited data on the effect of sacubitril-valsartan on the echocardiographic parameters in acute decompensated heart failure (ADHF). We prospectively enrolled 68 consecutive patients with ADHF who received sacubitril-valsartan (N = 34, S/V group) or angiotensin inhibition-based therapy (N = 34, ACEi/ARB group). Two-dimensional echocardiography with speckle tracking (2D-STE) was performed at baseline and after 3 months of treatment. Changes in 2D-STE parameters, including global longitudinal strain (GLS), were compared between the groups by t test and ANCOVA. Baseline characteristics were similar between the groups. Following 3 months of treatment, LVEF and GLS significantly improved in the S/V group (mean LVEF from 27 to 34.5% and GLS from - 6.6 to - 9.4%) but not in ACEi/ARB group. The improvement in LVEF and GLS was more prominent in patients with non-ischemic cardiomyopathy. In patients with ADHF 3-month treatment with sacubitril-valsartan, compared to guideline directed medical therapy without sacubitril, improves LVEF and GLS. Graphical Abstract A typical change in GLS in a patient with acute decompensated heart failure after 3 months of sacubitril-valsartan.All authors: Bakovic D, Barac A, Capkun V, Duplancic D, Eterovic D, Miric D, Soric T, Vukovic IOriginally published: Journal of Cardiovascular Translational Research . 14(2):290-298, 2021 Apr.Fiscal year: FY2021Fiscal year of original publication: FY2021Digital Object Identifier: ORCID: Date added to catalog: 2020-08-26
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 32557158 Available 32557158

There is limited data on the effect of sacubitril-valsartan on the echocardiographic parameters in acute decompensated heart failure (ADHF). We prospectively enrolled 68 consecutive patients with ADHF who received sacubitril-valsartan (N = 34, S/V group) or angiotensin inhibition-based therapy (N = 34, ACEi/ARB group). Two-dimensional echocardiography with speckle tracking (2D-STE) was performed at baseline and after 3 months of treatment. Changes in 2D-STE parameters, including global longitudinal strain (GLS), were compared between the groups by t test and ANCOVA. Baseline characteristics were similar between the groups. Following 3 months of treatment, LVEF and GLS significantly improved in the S/V group (mean LVEF from 27 to 34.5% and GLS from - 6.6 to - 9.4%) but not in ACEi/ARB group. The improvement in LVEF and GLS was more prominent in patients with non-ischemic cardiomyopathy. In patients with ADHF 3-month treatment with sacubitril-valsartan, compared to guideline directed medical therapy without sacubitril, improves LVEF and GLS. Graphical Abstract A typical change in GLS in a patient with acute decompensated heart failure after 3 months of sacubitril-valsartan.

English

Powered by Koha